|
**Overview**: Allergy Asthma Rhinitis Adult Panel**Introduction**: The Allergy Asthma Rhinitis Adult Panel is a diagnostic tool designed to screen for asthma/rhinitis allergens using serum samples. In India, allergic rhinitis affects ~20-30% adults, asthma ~37.5 million cases, with multi-allergen sensitization (dust mite dominant ~47-70%, cockroach 18-40%, pollen/mold regional). Urban pollution/pollen seasons exacerbate symptoms (wheezing, sneezing, nasal congestion). High morbidity from underdiagnosis in working adults, limited access. Per immunology practices (ICMR aligned), the test employs immunoassay for detailed parameter analysis over 1-2 days with high sensitivity/specificity, making it valuable for identifying triggers in persistent cases. This diagnostic falls under allergy screening and targets adults with asthma/rhinitis, addressing accurate detection to guide avoidance/immunotherapy. With morbidity elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing exacerbations. Its serum-based approach ensures reliable detection.**Other Names**: Allergy Asthma Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Expanded with specific IgE; in India, relevance with rising AR prevalence.**Purpose**: The test screens for 9 parameters including total IgE to guide assessment, identify triggers, inform treatment/prevention in adult populations.**Test Parameters**: 1. Total IgE, 2. House Dust Mite IgE, 3. Grass Pollen IgE, 4. Tree Pollen IgE, 5. Weed Pollen IgE, 6. Mold IgE, 7. Cat Dander IgE, 8. Dog Dander IgE, 9. Cockroach IgE.**Pretest Condition**: No fasting required; patients should report rhinitis/asthma symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, exposures, family history of atopy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated conditions including chronic asthma/rhinitis, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible triggers, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Allergists or pulmonologists should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Spirometry, nasal endoscopy for confirmation.**Test Limitations**: The test may produce false negatives in low exposure or false positives in sensitization without clinical disease, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: ICMR Allergy Guidelines 2023, Indian Journal Respiratory 2024. |
